Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as a complementary indicator to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3][9] Zacks Style Scores - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [5][6][7][8] - Each stock is rated from A to F based on its characteristics, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score identifies stocks that are undervalued based on financial ratios such as P/E, PEG, and Price/Sales [5] Growth Score - The Growth Style Score assesses a company's financial health and future growth potential through metrics like earnings and sales projections [6] Momentum Score - The Momentum Style Score focuses on stocks with favorable price trends, utilizing factors like recent price changes and earnings estimate revisions [7] VGM Score - The VGM Score combines the three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth, and momentum [8] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [10] - A significant number of stocks are rated under the Zacks Rank, with over 800 top-rated options available [11] Stock to Watch: Exelixis (EXEL) - Exelixis, Inc. is an oncology-focused biotechnology company engaged in developing treatments for challenging cancers [15] - EXEL holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 18.46 [16] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising to $1.93 per share [16] - With strong ratings and scores, EXEL is positioned as a notable investment opportunity [17]